{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:08:01Z","timestamp":1792728481937,"version":"4.5.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Retention in care is a prerequisite for successful recovery, especially for a chronic condition like opioid dependence. Though retention varies greatly depending on the different substitution medication and treatment model, treatment retention is used as an indicator of treatment quality and effectiveness of care on a system and individual level. To monitor the overall quality of the Austrian opioid agonist treatment (OAT) system and to monitor patient satisfaction within the system, a new online-based registry called \u201ceSuchmittel\u201d was introduced in Austria at the beginning of 2011. The objective of this study is to analyze retention rates within the Austrian treatment system and to identify patient characteristics associated with retention, using data collected by the substitution registry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The complete Austrian sample of 4778 registered patients starting treatment between 1.1.2011 to 31.12.2012 were included in the prospective cohort study using data from the Austrian substitution registry. For the statistical analysis, multivariate Cox Regression and Kaplan\u2013Meier survival analysis were used to evaluate retention in treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The retention rate of the total cohort after two years was around 61%. Retention rates were significantly lower for men (exp(B)\u2009=\u2009.806, 95% CI 0.714\u20130.908) and significantly higher for patients aged 30 and older (exp(B)\u2009=\u20091.155, 95% CI 1.044\u20131.279), among patients located in Vienna (exp(B)\u2009=\u20091.439, 95% CI 1.273\u20131.626) and among patients prescribed oral slow-release morphine (SROM) (exp(B)\u2009=\u20092.141, 95% CI 1.885\u20132.430).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Average retention in the Austrian system is high in comparison to international retention rates. Nationally, SROM demonstrates higher treatment retention when compared to other available substitution medications. Sociodemographic and regional indicators also contribute to higher retention in care. A systematic monitoring of retention rates within a national registry is an important tool helping to evaluate the quality of care. In this study, the Austrian OAT system proves very high retention in care, an important success criterion.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12954-021-00473-9","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T08:03:12Z","timestamp":1614153792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Retention in the Austrian opioid agonist treatment system: a national prospective cohort study"],"prefix":"10.1186","volume":"18","author":[{"given":"Martin","family":"Busch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Uhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Haltmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Cabanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4720-8402","authenticated-orcid":false,"given":"Jean Nicolas","family":"Westenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Michael","family":"Krausz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"issue":"2","key":"473_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0376-8716(03)00002-4","volume":"70","author":"J Esteban","year":"2003","unstructured":"Esteban J, Gimeno C, Barril J, Aragon\u00e9s A, Climent JM, de la Cruz Pellin M. Survival study of opioid addicts in relation to its adherence to methadone maintenance treatment. Drug Alcohol Depend. 2003;70(2):193\u2013200.","journal-title":"Drug Alcohol Depend"},{"key":"473_CR2","unstructured":"Busch M, Haas S, Weigl M, Wirl C. Long term substitution treatment (maintenance treatment) of opioid dependent persons. GMS Health Technol Assess. 2007;3."},{"key":"473_CR3","unstructured":"Kimber J, Palmateer N, Hutchinson SJ, Hickman M, Goldberg DJ, Rhodes T. Harm reduction among injecting drug users-evidence of effectiveness. 2010;"},{"issue":"1\u20133","key":"473_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.drugalcdep.2007.11.003","volume":"94","author":"T Clausen","year":"2008","unstructured":"Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2008;94(1\u20133):151\u20137.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"473_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1477-7517-4-5","volume":"4","author":"II Michels","year":"2007","unstructured":"Michels II, St\u00f6ver H, Gerlach R. Substitution treatment for opioid addicts in Germany. Harm Reduct J. 2007;4(1):5. https:\/\/doi.org\/10.1186\/1477-7517-4-5.","journal-title":"Harm Reduct J"},{"key":"473_CR6","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane database Syst Rev. 2009;(3).","DOI":"10.1002\/14651858.CD002209.pub2"},{"issue":"4","key":"473_CR7","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/j.1360-0443.2009.02856.x","volume":"105","author":"P Oliver","year":"2010","unstructured":"Oliver P, Keen J, Rowse G, Ewins E, Griffiths L, Mathers N. The effect of time spent in treatment and dropout status on rates of convictions, cautions and imprisonment over 5 years in a primary care-led methadone maintenance service. Addiction. 2010;105(4):732\u20139.","journal-title":"Addiction"},{"key":"473_CR8","unstructured":"European Centre for Disease Prevention and Control and European Monitoring Centre for Drugs, Drug and Addiction. Evidence for the effectiveness of interventions to prevent infections among people who inject drugs. Part 2: Drug treatment for preventing hepatitis C, HIV and injecting risk behaviour. [Internet]. ECDC, editor. Stockholm; 2011. http:\/\/www.ecdc.europa.eu\/en\/publications\/Publications\/111129_TER_ECDC-EMCDDA_report_part1.pdf"},{"issue":"5","key":"473_CR9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1046\/j.1360-0443.2003.00354.x","volume":"98","author":"Z Zhang","year":"2003","unstructured":"Zhang Z, Friedmann PD, Gerstein DR. Does retention matter? Treatment duration and improvement in drug use. Addiction. 2003;98(5):673\u201384.","journal-title":"Addiction"},{"issue":"4","key":"473_CR10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1037\/0893-164X.11.4.294","volume":"11","author":"DD Simpson","year":"1997","unstructured":"Simpson DD, Joe GW, Brown BS. Treatment retention and follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav. 1997;11(4):294.","journal-title":"Psychol Addict Behav"},{"issue":"6","key":"473_CR11","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3109\/00952990.2012.694516","volume":"38","author":"L Mullen","year":"2012","unstructured":"Mullen L, Barry J, Long J, Keenan E, Mulholland D, Grogan L, et al. A national study of the retention of Irish opiate users in methadone substitution treatment. Am J Drug Alcohol Abuse. 2012;38(6):551\u20138.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"473_CR12","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.","journal-title":"BMJ"},{"key":"473_CR13","doi-asserted-by":"publisher","first-page":"c5475","DOI":"10.1136\/bmj.c5475","volume":"341","author":"R Cornish","year":"2010","unstructured":"Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ. 2010;341:c5475.","journal-title":"BMJ"},{"issue":"3","key":"473_CR14","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0376-8716(97)00099-9","volume":"47","author":"DD Simpson","year":"1997","unstructured":"Simpson DD, Joe GW, Rowan-Szal GA. Drug abuse treatment retention and process effects on follow-up outcomes. Drug Alcohol Depend. 1997;47(3):227\u201335.","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"473_CR15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1176\/appi.ps.55.7.767","volume":"55","author":"Y-I Hser","year":"2004","unstructured":"Hser Y-I, Evans E, Huang D, Anglin DM. Relationship between drug treatment services, retention, and outcomes. Psychiatr Serv. 2004;55(7):767\u201374.","journal-title":"Psychiatr Serv"},{"issue":"1","key":"473_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","volume":"35","author":"C Timko","year":"2016","unstructured":"Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22\u201335.","journal-title":"J Addict Dis"},{"issue":"5","key":"473_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0232086","volume":"15","author":"AM O\u2019Connor","year":"2020","unstructured":"O\u2019Connor AM, Cousins G, Durand L, Barry J, Boland F. Retention of patients in opioid substitution treatment: a systematic review. PLoS ONE. 2020;15(5):1\u201323.","journal-title":"PLoS ONE"},{"issue":"10","key":"473_CR18","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2215-0366(15)00366-1","volume":"2","author":"J Kimber","year":"2015","unstructured":"Kimber J, Larney S, Hickman M, Randall D, Degenhardt L. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. Lancet Psychiatry. 2015;2(10):901\u20138.","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"473_CR19","doi-asserted-by":"publisher","first-page":"e025799","DOI":"10.1136\/bmjopen-2018-025799","volume":"9","author":"J Klimas","year":"2019","unstructured":"Klimas J, Gorfinkel L, Giacomuzzi SM, Ruckes C, Soc\u00edas ME, Fairbairn N, et al. Slow release oral morphine versus methadone for the treatment of opioid use disorder. BMJ Open. 2019;9(4):e025799.","journal-title":"BMJ Open"},{"issue":"3","key":"473_CR20","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jsat.2008.07.002","volume":"36","author":"JR Havens","year":"2009","unstructured":"Havens JR, Latkin CA, Pu M, Cornelius LJ, Bishai D, Huettner S, et al. Predictors of opiate agonist treatment retention among injection drug users referred from a needle exchange program. J Subst Abuse Treat. 2009;36(3):306\u201312. https:\/\/doi.org\/10.1016\/j.jsat.2008.07.002.","journal-title":"J Subst Abuse Treat"},{"issue":"2\u20133","key":"473_CR21","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.drugalcdep.2011.01.008","volume":"117","author":"SM Kelly","year":"2011","unstructured":"Kelly SM, O\u2019Grady KE, Mitchell SG, Brown BS, Schwartz RP. Predictors of methadone treatment retention from a multi-site study: a survival analysis. Drug Alcohol Depend. 2011;117(2\u20133):170\u20135. https:\/\/doi.org\/10.1016\/j.drugalcdep.2011.01.008.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"473_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jsat.2011.07.009","volume":"42","author":"R Sarasvita","year":"2012","unstructured":"Sarasvita R, Tonkin A, Utomo B, Ali R. Predictive factors for treatment retention in methadone programs in Indonesia. J Subst Abuse Treat. 2012;42(3):239\u201346. https:\/\/doi.org\/10.1016\/j.jsat.2011.07.009.","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"473_CR23","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.drugalcdep.2005.11.020","volume":"83","author":"SW Villafranca","year":"2006","unstructured":"Villafranca SW, McKellar JD, Trafton JA, Humphreys K. Predictors of retention in methadone programs: a signal detection analysis. Drug Alcohol Depend. 2006;83(3):218\u201324.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"473_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/002204269702700202","volume":"27","author":"CE Grella","year":"1997","unstructured":"Grella CE, Wugalter SE, Anglin MD. Predictors of treatment retention in enhanced and standard methadone maintenance treatment for HIV risk reduction. J Drug Issues. 1997;27(2):203\u201324.","journal-title":"J Drug Issues"},{"issue":"10","key":"473_CR25","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1111\/j.1530-0277.2000.tb04571.x","volume":"24","author":"JR Mertens","year":"2000","unstructured":"Mertens JR, Weisner CM. Predictors of substance abuse treatment retention among women and men in an HMO. Alcohol Clin Exp Res. 2000;24(10):1525\u201333.","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"473_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1477-7517-10-3","volume":"10","author":"F Yang","year":"2013","unstructured":"Yang F, Lin P, Li Y, He Q, Long Q, Fu X, et al. Predictors of retention in community-based methadone maintenance treatment program in Pearl River Delta, China. Harm Reduct J. 2013;10(1):3.","journal-title":"Harm Reduct J"},{"issue":"1","key":"473_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12954-020-00396-x","volume":"17","author":"KA Morin","year":"2020","unstructured":"Morin KA, Eibl JK, Gauthier G, Rush B, Mushquash C, Lightfoot NE, et al. A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data. Harm Reduct J. 2020;17(1):51. https:\/\/doi.org\/10.1186\/s12954-020-00396-x.","journal-title":"Harm Reduct J"},{"key":"473_CR28","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Drug policy profile: Austria [Internet]. Luxembourg; 2014. https:\/\/www.emcdda.europa.eu\/system\/files\/publications\/777\/TDAU14004ENN_469059.pdf"},{"key":"473_CR29","unstructured":"Horvath I, Anzenberger J, Busch M, Schmutterer I, Tanios A, Weigl M. Bericht zur Drogensituation 2019. 2019;"},{"key":"473_CR30","unstructured":"Haltmayer H. Oral Substitution Treatment in Austria\u2014the role of GPs [Internet]. 2010. https:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_118398_EN_Dr Haltmayer_Austria.pdf"},{"key":"473_CR31","unstructured":"Legal Information System of the Republic of Austria. Consolidated federal law: Entire legal provision for the Narcotics Act, version of January 27, 2021 [Internet]. 2021. https:\/\/www.ris.bka.gv.at\/GeltendeFassung.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10011040"},{"key":"473_CR32","unstructured":"Legal Information System of the Republic of Austria. Consolidated federal law: Entire legal provision for further training ordinance on opioid substitution, version of January 27, 2021. 2021."},{"key":"473_CR33","unstructured":"EMCDDA. Mortality among drug users: Guidelines for carrying out, analysing and reporting key figures [Internet]. Lisbon; 2012. http:\/\/www.emcdda.europa.eu\/attachements.cfm\/att_192545_EN_MortalityCohortsGuidelines2012.pdf"},{"key":"473_CR34","unstructured":"SPSS Inc. SPSS Statistics, Version 17.0. Chicago, United States; 2008."},{"issue":"4","key":"473_CR35","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jclinepi.2007.11.006","volume":"61","author":"A Knottnerus","year":"2008","unstructured":"Knottnerus A, Tugwell P. STROBE\u2013a checklist to strengthen the reporting of observational studies in epidemiology. J Clin Epidemiol. 2008;61(4):323.","journal-title":"J Clin Epidemiol"},{"key":"473_CR36","unstructured":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Austria, Country Drug Report 2017. Luxembourg; 2017."},{"issue":"1","key":"473_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF02287327","volume":"32","author":"D Deck","year":"2005","unstructured":"Deck D, Carlson MJ. Retention in publicly funded methadone maintenance treatment in two western states. J Behav Health Serv Res. 2005;32(1):43\u201360.","journal-title":"J Behav Health Serv Res"},{"issue":"1","key":"473_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0376-8716(96)01230-6","volume":"41","author":"M Torrens","year":"1996","unstructured":"Torrens M, Castillo C, P\u00e9rez-Sol\u00e1 V. Retention in a low-threshold methadone maintenance program. Drug Alcohol Depend. 1996;41(1):55\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"473_CR39","doi-asserted-by":"publisher","first-page":"A194","DOI":"10.1016\/j.jval.2013.03.978","volume":"16","author":"J Ren","year":"2013","unstructured":"Ren J, Ning Z, Asche C, Zhuang M, Kirkness CS, Ye X, et al. Determinants on compliance of methadone maintenance treatment in Shanghai, China. Value Heal. 2013;16(3):A194.","journal-title":"Value Heal"},{"issue":"4","key":"473_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/10550880802324382","volume":"27","author":"E Peles","year":"2008","unstructured":"Peles E, Linzy S, Kreek MJ, Adelson M. One-year and cumulative retention as predictors of success in methadone maintenance treatment: a comparison of two clinics in the United States and Israel. J Addict Dis. 2008;27(4):11\u201325.","journal-title":"J Addict Dis"},{"issue":"1","key":"473_CR41","first-page":"65","volume":"64","author":"WP Sharifa Ezat","year":"2009","unstructured":"Sharifa Ezat WP, Noor Azimah H, Rushidi R, Raminder K, Ruhani I. Compliance towards methadone maintenance therapy and its associated factors in Selangor primary care centers and Kuala Lumpur hospital. Med J Malaysia. 2009;64(1):65\u201370.","journal-title":"Med J Malaysia"},{"issue":"2","key":"473_CR42","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0376-8716(98)00091-X","volume":"52","author":"D D\u2019Ippoliti","year":"1998","unstructured":"D\u2019Ippoliti D, Davoli M, Perucci CA, Pasqualini F, Bargagli AM. Retention in treatment of heroin users in Italy: the role of treatment type and of methadone maintenance dosage. Drug Alcohol Depend. 1998;52(2):167\u201371.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"473_CR43","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0740-5472(03)00188-0","volume":"25","author":"K Beardsley","year":"2003","unstructured":"Beardsley K, Wish ED, Fitzelle DB, O\u2019Grady K, Arria AM. Distance traveled to outpatient drug treatment and client retention. J Subst Abuse Treat. 2003;25(4):279\u201385.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"473_CR44","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/add.12440","volume":"109","author":"T Beck","year":"2014","unstructured":"Beck T, Haasen C, Verthein U, Walcher S, Schuler C, Backmund M, et al. Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone. Addiction. 2014;109(4):617\u201326.","journal-title":"Addiction"},{"issue":"6","key":"473_CR45","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1111\/j.1365-2125.2011.03923.x","volume":"71","author":"J Jegu","year":"2011","unstructured":"Jegu J, Gallini A, Soler P, Montastruc J, Lapeyre-Mestre M. Slow-release oral morphine for opioid maintenance treatment: a systematic review. Br J Clin Pharmacol. 2011;71(6):832\u201343.","journal-title":"Br J Clin Pharmacol"},{"key":"473_CR46","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.drugalcdep.2018.04.026","volume":"189","author":"ME Soc\u00edas","year":"2018","unstructured":"Soc\u00edas ME, Wood E, Kerr T, Nolan S, Hayashi K, Nosova E, et al. Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006\u20132016. Drug Alcohol Depend. 2018;189:90\u20135.","journal-title":"Drug Alcohol Depend"},{"key":"473_CR47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.drugalcdep.2018.08.024","volume":"193","author":"S Amiri","year":"2018","unstructured":"Amiri S, Hirchak K, Lutz R, McDonell MG, McPherson SM, Roll JM, et al. Three-year retention in methadone opioid agonist treatment: a survival analysis of clients by dose, area deprivation, and availability of alcohol and cannabis outlets. Drug Alcohol Depend. 2018;193:63\u20138.","journal-title":"Drug Alcohol Depend"},{"key":"473_CR48","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.drugpo.2017.05.014","volume":"48","author":"K Dumchev","year":"2017","unstructured":"Dumchev K, Dvoryak S, Chernova O, Morozova O, Altice FL. Retention in medication-assisted treatment programs in Ukraine\u2014Identifying factors contributing to a continuing HIV epidemic. Int J Drug Policy. 2017;48:44\u201353.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"473_CR49","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.drugalcdep.2005.09.004","volume":"82","author":"E Peles","year":"2006","unstructured":"Peles E, Schreiber S, Adelson M. Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. Drug Alcohol Depend. 2006;82(3):211\u20137.","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"473_CR50","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1016\/j.addbeh.2014.05.007","volume":"39","author":"A Bukten","year":"2014","unstructured":"Bukten A, Skurtveit S, Waal H, Clausen T. Factors associated with dropout among patients in opioid maintenance treatment (OMT) and predictors of re-entry. A national registry-based study. Addict Behav. 2014;39(10):1504\u20139.","journal-title":"Addict Behav"},{"issue":"6","key":"473_CR51","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1097\/01.jcp.0000245561.99036.49","volume":"26","author":"M Soyka","year":"2006","unstructured":"Soyka M, Apelt SM, Lieb M, Wittchen H-U. One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients. J Clin Psychopharmacol. 2006;26(6):657\u201360.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"473_CR52","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11920-017-0783-9","volume":"19","author":"A Sharma","year":"2017","unstructured":"Sharma A, Kelly SM, Mitchell SG, Gryczynski J, O\u2019Grady KE, Schwartz RP. Update on barriers to pharmacotherapy for opioid use disorders. Curr Psychiatry Rep. 2017;19(6):35.","journal-title":"Curr Psychiatry Rep"},{"issue":"3","key":"473_CR53","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/1475-6773.13282","volume":"55","author":"AK Gertner","year":"2020","unstructured":"Gertner AK, Robertson AG, Jones H, Powell BJ, Silberman P, Domino ME. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints. Health Serv Res. 2020;55(3):383\u201392.","journal-title":"Health Serv Res"},{"issue":"12","key":"473_CR54","doi-asserted-by":"publisher","first-page":"e1208","DOI":"10.1016\/S2214-109X(17)30373-X","volume":"5","author":"S Larney","year":"2017","unstructured":"Larney S, Peacock A, Leung J, Colledge S, Hickman M, Vickerman P, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Heal. 2017;5(12):e1208\u201320. https:\/\/doi.org\/10.1016\/S2214-109X(17)30373-X.","journal-title":"Lancet Glob Heal"},{"key":"473_CR55","unstructured":"Wells C, Jones S. Sustained Release Oral Morphine, Injectable Hydromorphone , and Prescription Diacetylmorphine for Opioid Use Disorder: Clinical and. Ottawa; 2017."},{"issue":"4","key":"473_CR56","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jsat.2014.05.012","volume":"47","author":"R H\u00e4mmig","year":"2014","unstructured":"H\u00e4mmig R, K\u00f6hler W, Bonorden-Kleij K, Weber B, Lebentrau K, Berthel T, et al. Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence. J Subst Abuse Treat. 2014;47(4):275\u201381.","journal-title":"J Subst Abuse Treat"},{"key":"473_CR57","doi-asserted-by":"crossref","unstructured":"Kimmel S, Bach P, Walley AY. Comparison of Treatment Options for Refractory Opioid Use Disorder in the United States and Canada: a Narrative Review. J Gen Intern Med. 2020;1\u20139.","DOI":"10.1007\/s11606-021-06727-3"},{"issue":"2","key":"473_CR58","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/10826080500391845","volume":"41","author":"S Giacomuzzi","year":"2006","unstructured":"Giacomuzzi S, Kemmler G, Ertl M, Riemer Y. Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants. Subst Use Misuse. 2006;41(2):223\u201344.","journal-title":"Subst Use Misuse"},{"issue":"8","key":"473_CR59","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/j.1360-0443.2005.001128.x","volume":"100","author":"H Eder","year":"2005","unstructured":"Eder H, Jagsch R, Kraigher D, Primorac A, Ebner N, Fischer G. Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. Addiction. 2005;100(8):1101\u20139.","journal-title":"Addiction"},{"key":"473_CR60","first-page":"s33","volume":"66","author":"NKK Clark","year":"2002","unstructured":"Clark NKK, Lintzeris N, Ritter A, Whelan G. A randomised trial of once-daily slow-release oral morphine versus methadone for heroin dependence. Drug Alcohol Depend. 2002;66:s33.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"473_CR61","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/j.1465-3362.2011.00353.x","volume":"31","author":"AJ Bond","year":"2012","unstructured":"Bond AJ, Reed KD, Beavan P, Strang J. After the randomised injectable opiate treatment trial: Post-trial investigation of slow-release oral morphine as an alternative opiate maintenance medication. Drug Alcohol Rev. 2012;31(4):492\u20138.","journal-title":"Drug Alcohol Rev"},{"issue":"11","key":"473_CR62","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1111\/j.1360-0443.2008.02334.x","volume":"103","author":"A Kastelic","year":"2008","unstructured":"Kastelic A, Dubajic G, Strbad E. Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression. Addiction. 2008;103(11):1837\u201346.","journal-title":"Addiction"},{"issue":"9","key":"473_CR63","doi-asserted-by":"publisher","first-page":"E247","DOI":"10.1503\/cmaj.170958","volume":"190","author":"J Bruneau","year":"2018","unstructured":"Bruneau J, Ahamad K, Goyer M\u00c8, Poulin G, Selby P, Fischer B, et al. Management of opioid use disorders: a national clinical practice guideline. CMAJ. 2018;190(9):E247\u201357.","journal-title":"CMAJ"},{"issue":"1","key":"473_CR64","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/add.14442","volume":"114","author":"C Nordt","year":"2019","unstructured":"Nordt C, Vogel M, Dey M, Moldovanyi A, Beck T, Berthel T, et al. One size does not fit all\u2014evolution of opioid agonist treatments in a naturalistic setting over 23 years. Addiction. 2019;114(1):103\u201311.","journal-title":"Addiction"},{"key":"473_CR65","doi-asserted-by":"publisher","first-page":"105993","DOI":"10.1016\/j.cct.2020.105993","volume":"91","author":"ME Socias","year":"2020","unstructured":"Socias ME, Wood E, Dong H, Brar R, Bach P, Murphy SM, et al. Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): Protocol for a non-inferiority randomized clinical trial. Contemp Clin Trials. 2020;91:105993.","journal-title":"Contemp Clin Trials"},{"issue":"02","key":"473_CR66","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1055\/s-0033-1341453","volume":"14","author":"R Jagsch","year":"2013","unstructured":"Jagsch R, Fischer G, K\u00f6chl B, Unger A. Buprenorphin\/Naloxon\u2013Ergebnisse aus dem niedergelassenen Bereich. Suchttherapie. 2013;14(02):84\u201391.","journal-title":"Suchttherapie"},{"key":"473_CR67","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/SAR.S109919","volume":"7","author":"R H\u00e4mmig","year":"2016","unstructured":"H\u00e4mmig R, Kemter A, Strasser J, von Bardeleben U, Gugger B, Walter M, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil. 2016;7:99\u2013105.","journal-title":"Subst Abuse Rehabil"},{"issue":"4","key":"473_CR68","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/ajad.12869","volume":"28","author":"S Klaire","year":"2019","unstructured":"Klaire S, Zivanovic R, Barbic SP, Sandhu R, Mathew N, Azar P. Rapid micro-induction of buprenorphine\/naloxone for opioid use disorder in an inpatient setting: a case series. Am J Addict. 2019;28(4):262\u20135.","journal-title":"Am J Addict"},{"issue":"1","key":"473_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13722-020-0177-x","volume":"15","author":"J Rozylo","year":"2020","unstructured":"Rozylo J, Mitchell K, Nikoo M, Durante SE, Barbic SP, Lin D, et al. Case report: Successful induction of buprenorphine\/naloxone using a microdosing schedule and assertive outreach. Addict Sci Clin Pract. 2020;15(1):1\u20136.","journal-title":"Addict Sci Clin Pract"},{"issue":"8","key":"473_CR70","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1111\/j.1360-0443.2009.02633.x","volume":"104","author":"L Burns","year":"2009","unstructured":"Burns L, Randall D, Hall WD, Law M, Butler T, Bell J, et al. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction. 2009;104(8):1363\u201372.","journal-title":"Addiction"},{"issue":"1","key":"473_CR71","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/1471-244X-13-262","volume":"13","author":"A Bukten","year":"2013","unstructured":"Bukten A, R\u00f8islien J, Skurtveit S, Waal H, Gossop M, Clausen T. A day-by-day investigation of changes in criminal convictions before and after entering and leaving opioid maintenance treatment: a national cohort study. BMC Psychiatry. 2013;13(1):262.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"473_CR72","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12954-020-00394-z","volume":"17","author":"D Crowley","year":"2020","unstructured":"Crowley D, Delargy I. A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report. Harm Reduct J. 2020;17(1):49. https:\/\/doi.org\/10.1186\/s12954-020-00394-z.","journal-title":"Harm Reduct J"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00473-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-021-00473-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00473-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T04:12:31Z","timestamp":1619410351000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-021-00473-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["473"],"URL":"https:\/\/doi.org\/10.1186\/s12954-021-00473-9","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,24]]},"assertion":[{"value":"20 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval to conduct the study was gained from the Austrian Federal Ministry of Health.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This study only used administrative health data, there was no primary data collection; therefore, consent for publication from individual patients did not apply.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}